Targacept Slammed on Failed Drug Trial (TRGT, AZN)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a trial in which the drug did no better than placebo. The writing has been on the wall on TC-5214 since an announcement in December that the drug had failed to meet its endpoint in a phase II trial.

Targacept’s CEO said that the company has been preparing for this possibility and that it will announce its plans by the end of April. The company has more than $225 million in cash available according to the CEO.

Targacept’s shares are down -27% at $5.41 in a 52-week range of $4.91-$27.22. AstraZeneca’s shares are up about 0.4% at $45.58 in a 52-week range of $40.89-$52.54.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

ABNB Vol: 15,913,532
MCHP Vol: 19,139,274
PLTR Vol: 77,244,625
MRNA Vol: 6,820,582
AXON Vol: 1,591,869

Top Losing Stocks

TTD Vol: 133,458,224
CTRA Vol: 73,319,495
AKAM Vol: 8,143,961
ZTS Vol: 12,784,553
RMD Vol: 3,810,438